Ritterhouse Lauren L, Howitt Brooke E
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Surg Pathol Clin. 2016 Sep;9(3):405-26. doi: 10.1016/j.path.2016.04.006.
This article focuses on the diagnostic, prognostic, and predictive molecular biomarkers in uterine malignancies, in the context of morphologic diagnoses. The histologic classification of endometrial carcinomas is reviewed first, followed by the description and molecular classification of endometrial epithelial malignancies in the context of histologic classification. Taken together, the molecular and histologic classifications help clinicians to approach troublesome areas encountered in clinical practice and evaluate the utility of molecular alterations in the diagnosis and subclassification of endometrial carcinomas. Putative prognostic markers are reviewed. The use of molecular alterations and surrogate immunohistochemistry as prognostic and predictive markers is also discussed.
本文聚焦于形态学诊断背景下子宫恶性肿瘤的诊断、预后及预测分子生物标志物。首先回顾子宫内膜癌的组织学分类，接着在组织学分类的背景下描述并阐述子宫内膜上皮恶性肿瘤的分子分类。综合来看，分子分类和组织学分类有助于临床医生处理临床实践中遇到的棘手问题，并评估分子改变在子宫内膜癌诊断及亚分类中的效用。本文还对假定的预后标志物进行了综述。同时也讨论了分子改变及替代免疫组化作为预后和预测标志物的应用。
